The corneal endothelial dystrophy market size is expected to see strong growth in the next few years. It will grow to $252.88 billion in 2029 at a compound annual growth rate (CAGR) of 8.1%.” ...

In eyes with keratoconus, no contact lens — whether soft, gas permeable or scleral — can arrest progression of the underlying ...

WASHINGTON (AP) — Sarepta Therapeutics said Tuesday that a patient died while taking its closely watched gene therapy for muscular dystrophy, sending company shares plummeting in morning trading.

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window A young person with Duchenne muscular dystrophy died following treatment with the recently approved gene therapy ...

Sarepta Therapeutics Inc.’s stock tumbled 23% on Tuesday after the biotech said a patient who used its gene therapy Elevidys for the rare disease Duchenne muscular dystrophy has died of acute ...

A patient has died following treatment with Elevidys, the Sarepta Therapeutics product that is the only FDA-approved gene therapy for Duchenne muscular dystrophy, the company disclosed Tuesday.

its FDA-approved treatment for Duchenne muscular dystrophy. In a statement, the Cambridge, Massachusetts-based biotech said that a young man with DMD died after receiving Elevidys, a gene therapy ...

His meeting with a specialist was an eye-opener. That’s when his doctor said, “I’m pretty sure you’ve got cornea dystrophy. I’m going to have to replace your cornea." It was something ...

Considering taking supplements to treat muscular dystrophy? Below is a list of common natural remedies used to treat or reduce the symptoms of muscular dystrophy. Follow the links to read common ...

Patients with Fuchs endothelial corneal dystrophy with particular genetic markers are at higher risk for surgery and vision loss.